These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 3112095

  • 1. In-vitro activity of six fluorinated quinolones against Mycobacterium tuberculosis.
    Berlin OG, Young LS, Bruckner DA.
    J Antimicrob Chemother; 1987 May; 19(5):611-5. PubMed ID: 3112095
    [Abstract] [Full Text] [Related]

  • 2. Comparative antimicrobial activity of enoxacin, ciprofloxacin, amifloxacin, norfloxacin and ofloxacin against 177 bacterial isolates.
    Bassey CM, Baltch AL, Smith RP.
    J Antimicrob Chemother; 1986 May; 17(5):623-8. PubMed ID: 2941401
    [Abstract] [Full Text] [Related]

  • 3. [In vitro activity of new quinolones against Mycoplasma pathogenic to humans].
    Renaudin H, Quentin C, de Barbeyrac B, Bebear C.
    Pathol Biol (Paris); 1988 May; 36(5):496-9. PubMed ID: 3136430
    [Abstract] [Full Text] [Related]

  • 4. Comparative in-vitro activity of five fluoroquinolones against mycobacteria.
    Davies S, Sparham PD, Spencer RC.
    J Antimicrob Chemother; 1987 May; 19(5):605-9. PubMed ID: 3112094
    [Abstract] [Full Text] [Related]

  • 5. In vitro evaluation of A-56619 and A-56620, two new quinolones.
    Barry AL, Thornsberry C, Jones RN.
    Antimicrob Agents Chemother; 1986 Jan; 29(1):40-3. PubMed ID: 2942099
    [Abstract] [Full Text] [Related]

  • 6. The comparative in-vitro activity of eight newer quinolones and nalidixic acid.
    King A, Phillips I.
    J Antimicrob Chemother; 1986 Nov; 18 Suppl D():1-20. PubMed ID: 3468100
    [Abstract] [Full Text] [Related]

  • 7. Comparative in vitro activities of pefloxacin, ofloxacin, enoxacin and ciprofloxacin against 256 clinical isolates.
    Arpi M, Gahrn-Hansen B, Søgaard P, Bentzon MW.
    Acta Pathol Microbiol Immunol Scand B; 1987 Apr; 95(2):141-6. PubMed ID: 3473910
    [Abstract] [Full Text] [Related]

  • 8. Comparative in vitro activity of amifloxacin and five other fluoroquinolone antimicrobial agents and preliminary criteria for the disk susceptibility test.
    Barry AL, Jones RN.
    Eur J Clin Microbiol; 1987 Apr; 6(2):179-82. PubMed ID: 3474145
    [Abstract] [Full Text] [Related]

  • 9. In vitro comparison of A-56619, A-56620, amifloxacin, ciprofloxacin, enoxacin, norfloxacin, and ofloxacin against methicillin-resistant Staphylococcus aureus.
    Smith SM.
    Antimicrob Agents Chemother; 1986 Feb; 29(2):325-6. PubMed ID: 2940966
    [Abstract] [Full Text] [Related]

  • 10. In vitro susceptibility of aerobic gram-negative blood culture isolates to oxolinic acid, norfloxacin, ciprofloxacin, enoxacin, pefloxacin, ofloxacin and oxo-enoxacin.
    Van der Auwera P.
    Infection; 1986 Feb; 14(3):142-4. PubMed ID: 2942489
    [Abstract] [Full Text] [Related]

  • 11. Comparative in-vitro activity of Ro 23-6240, a new trifluorinated quinolone.
    Verbist L.
    J Antimicrob Chemother; 1987 Sep; 20(3):363-72. PubMed ID: 3119552
    [Abstract] [Full Text] [Related]

  • 12. Frequency and expression of mutational resistance to the 4-quinolone antibacterials.
    Smith JT.
    Scand J Infect Dis Suppl; 1986 Sep; 49():115-23. PubMed ID: 3547618
    [Abstract] [Full Text] [Related]

  • 13. [In vitro activity of new quinolones against nonfermenters and references to sensitivity tests].
    Grimm H.
    Infection; 1986 Sep; 14 Suppl 3():S191-5. PubMed ID: 3093387
    [Abstract] [Full Text] [Related]

  • 14. In vitro activity of five new quinolones against cultivable mycobacteria.
    Pattyn SR, Van Caekenberghe DL, Verhoeven JR.
    Eur J Clin Microbiol; 1987 Oct; 6(5):572-3. PubMed ID: 3125049
    [No Abstract] [Full Text] [Related]

  • 15. [Comparative in vitro activity of 10 new 4-quinolones against enteropathogenic bacteria].
    Habiyaremye I, Verbist L, Vandepitte J.
    Pathol Biol (Paris); 1987 Jun; 35(5 Pt 2):800-4. PubMed ID: 3116489
    [Abstract] [Full Text] [Related]

  • 16. In-vitro activity of newer quinolones against aerobic bacteria.
    Auckenthaler R, Michéa-Hamzehpour M, Pechère JC.
    J Antimicrob Chemother; 1986 Apr; 17 Suppl B():29-39. PubMed ID: 2940214
    [Abstract] [Full Text] [Related]

  • 17. Comparative in vitro activity of seven quinolones against 100 clinical isolates of Clostridium difficile.
    Delmee M, Avesani V.
    Antimicrob Agents Chemother; 1986 Feb; 29(2):374-5. PubMed ID: 2940968
    [Abstract] [Full Text] [Related]

  • 18. Comparative in vitro activities of ciprofloxacin, enoxacin, norfloxacin, ofloxacin and pefloxacin against Bacteroides fragilis and Clostridium difficile.
    Edlund C, Nord CE.
    Scand J Infect Dis; 1986 Feb; 18(2):149-51. PubMed ID: 2939556
    [Abstract] [Full Text] [Related]

  • 19. The in-vitro activities of enoxacin and ofloxacin compared with that of ciprofloxacin.
    King A, Shannon K, Phillips I.
    J Antimicrob Chemother; 1985 May; 15(5):551-8. PubMed ID: 3159712
    [Abstract] [Full Text] [Related]

  • 20. In vitro susceptibility of Mycobacterium tuberculosis to ofloxacin and ciprofloxacin in combination with rifampin and isoniazid.
    Casal M, Gutierrez J, González J, Ruiz P.
    Chemioterapia; 1987 Dec; 6(6):437-9. PubMed ID: 3124964
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.